@article{d341bea36c71462881c565fd26e4befd,
title = "BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee",
abstract = "The Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 1, 2016 at the American Society of Hematology meeting to discuss the emerging data and technologies for minimal residual disease assessment and immune profiling in myeloma. Particular emphasis was placed on developing strategies to incorporate these techniques into clinical trial design. This document reviews the literature, summarizes the topics discussed in the workshop, and provides recommendations for integration of these techniques into future clinical trial design.",
keywords = "Immune profiling, Minimal residual disease, Multiple myeloma, autologous stem cell transplant",
author = "Holstein, {Sarah A.} and Herv{\'e} Avet-Loiseau and Theresa Hahn and Ho, {Christine M.} and Lohr, {Jens G.} and Munshi, {Nikhil C.} and Bruno Paiva and Pasquini, {Marcelo C.} and Tario, {Joseph D.} and Usmani, {Saad Z.} and Wallace, {Paul K.} and Katja Weisel and McCarthy, {Philip L.}",
note = "Funding Information: Conflict of interest statement: S.A.H. has served on advisory boards and received honoraria from Celgene, Amgen, and Takeda. H.A.L. has served as a consultant for Amgen, Celgene, Sanofi, and Janssen. T.H. has received research funding from Celgene. N.C.M. has served as a consultant for Celgene, Pfizer, Merck, Oncopep, and Takeda and has equity ownership in Oncopep. S.Z.U. has served on Speakers Bureaus for Onyx, Celgene, Millennium, Novartis, Sanofi, and BioPharma; has served as a consultant for Amgen, Celgene, Sanofi, and Takeda; and has received honoraria from Array, Bristol-Myers Squibb, Janssen, and Pharmacyclics. K.W. has received institutional research funding from Amgen, Celgene, and Sanofi. P.L.M. has received honoraria from Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, and Binding Site; has recieved research funding from Celgene; and has served on advisory committees/review panels/board membership for Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, Binding Site, and Karyopharm. Funding Information: Financial disclosure: Support for the Blood and Marrow Transplant Clinical Trials Network was provided by grant U10HL069294 from the National Heart, Lung, and Blood Institute and the National Cancer Institute . Support for the PRIMeR ancillary study was provided by National Heart, Lung, and Blood Institute grant R01HL107213 . Publisher Copyright: {\textcopyright} 2017 The American Society for Blood and Marrow Transplantation",
year = "2018",
month = apr,
doi = "10.1016/j.bbmt.2017.12.774",
language = "English (US)",
volume = "24",
pages = "641--648",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",
}